(TLSI) TriSalus Life Sciences, Inc. Business Model Canvas Research

TriSalus Life Sciences, Inc. relies on manufacturing and component suppliers to lock in controlled sourcing for devices, drugs, and sterile fill-finish capacity. This keeps quality and supply continuity tight for both commercial launches and investigational supply.

These partners matter most where batch control and traceability drive risk; a single disrupted lot can delay both commercialization and clinical programs.

• Controlled materials sourcing
• Sterile production capacity
• Quality and lot consistency
• Supply continuity for trials

TriSalus Life Sciences, Inc. depends on FDA review paths and payer coverage to turn oncology devices and therapies into revenue. With Medicare covering about 66 million people, evidence tied to safety, outcomes, and cost can speed adoption or stall sales.

So TriSalus must match trial design and real-world data to FDA and reimbursement demands, because coverage decisions shape timing, volume, and commercialization scale.

• FDA evidence drives market entry.
• Payer coverage drives adoption speed.
• Clinical data must support both.

Regulatory compliance is a core TriSalus Life Sciences activity because its products must clear FDA medical device and biologic rules, including quality systems, documentation, and submission support. For U.S. commercialization and clinical studies, work often ties to 21 CFR Parts 820 and 812, where missing records or controls can delay approval and site activation.

• FDA device and biologic compliance
• Quality systems and full documentation
• Submission support for trials and launch

TriSalus must train physicians and help hospitals implement the workflow, because the value of its therapy depends on correct delivery technique, patient selection, and realistic outcome expectations. Commercial support turns clinical interest into actual use by reducing setup friction at the point of care.

• Train physicians on delivery technique

• Guide patient selection and outcomes

• Support hospital workflow rollout

• Convert interest into routine use

Pressure-enabled delivery technology is TriSalus Life Sciences, Inc.'s core platform resource, designed to improve intratumoral and regional drug delivery by using pressure to push therapy deeper into solid tumors. It supports multiple indications, including liver and pancreatic cancers, and can be reused across future pipeline assets, which lowers retooling needs and helps spread R&D spend across programs.

• Core platform, not one product
• Improves local tumor drug delivery
• Supports multiple cancer indications
• Reusable across future pipeline

TriSalus Life Sciences, Inc.’s oncology development team is the core human asset behind device design, clinical trials, regulatory work, and launch prep, with the group centered in Westminster, Colorado. The latest public filings show TriSalus is still a small-cap development company, so this mix of scientists, clinicians, regulators, and commercial staff is critical to turn R&D spend into approved products and revenue.

• Westminster, Colorado hub
• Science, clinical, regulatory, commercial roles
• Drives device, trial, and launch execution

TriSalus Life Sciences, Inc. uses pressure-enabled drug delivery to push therapy deeper into tumor tissue, aiming to raise local drug exposure where blood flow is poor. That matters most in hard-to-treat solid tumors, and it is a core differentiator across the portfolio because better delivery can support better response.

• Improves tumor-site drug exposure
• Targets poorly perfused tumors
• Sets the platform apart

TriSalus Life Sciences, Inc.'s multi-indication oncology platform spans HCC, ICC, uveal melanoma liver metastases, PDAC liver metastases, colorectal liver metastases, and primary pancreatic cancers, so one delivery model can serve several high-need tumors. Liver cancer alone caused about 760,000 deaths in 2022, which shows the size of the unmet need and supports combo and expansion use cases.

• Six tumor settings
• Broader addressable market
• Supports combo trials

Key opinion leaders in interventional oncology and hepatology can speed TriSalus Life Sciences, Inc. adoption because they shape procedure choices, validate clinical use, and strengthen peer trust. Their feedback also supports referral links and keeps the company’s field message credible with specialists who drive liver-care decisions.

• Validate procedures
• Build specialist trust
• Support referrals
• Improve clinical credibility

Medical device buyers expect help after install and first use, so TriSalus Life Sciences, Inc. should answer troubleshooting, procedural questions, and workflow issues fast. Bain found a 5% lift in retention can raise profits 25% to 95%, so reliable post-sale support directly supports repeat use and renewal.

• Fast fixes reduce downtime
• Procedure help builds trust
• Workflow fit drives repeat use

Medical education programs help TriSalus Life Sciences turn device and therapy know-how into real clinical use through workshops, live demonstrations, and peer-to-peer training, which matters most for procedural products. In 2025, TriSalus reported a net loss of about $60.4 million and ended the year with roughly $68.9 million in cash and equivalents, so education is a key way to support adoption without heavy direct selling.

• Builds clinician confidence
• Supports procedural adoption
• Uses workshops and demos
• Fits complex therapy products

Company website and digital materials are a key channel for TriSalus Life Sciences, Inc. They share product details, pipeline updates, and platform science for researchers, physicians, and partners, while also supporting recruiting and investor outreach.

• Shares product and pipeline updates
• Builds corporate visibility
• Supports hiring and investor communication

Clinical investigators running oncology trials are core users of TriSalus Life Sciences, Inc. SD-101 work, because they test the platform across multiple tumor types and generate the clinical evidence needed for later regulatory and market decisions. In 2025, oncology remained the largest drug development area, so their readouts matter for go or no-go calls.

• Test SD-101 across tumor types.
• Generate evidence for regulators.
• Shape market launch decisions.

TriSalus Life Sciences, Inc. serves patients with HCC, ICC, metastatic liver disease, and pancreatic cancer, where few options work well. These cancers drive the need: liver cancer caused about 830,000 deaths globally in 2022, and pancreatic cancer about 510,000, so demand stays high in hard-to-treat settings.

• HCC and ICC are key liver targets
• Metastatic liver disease expands the pool
• Pancreatic cancer need is severe

Regulatory and legal costs are a core drag on TriSalus Life Sciences, Inc. because FDA submissions, quality-system documentation, and IP protection all scale with each new product or indication. In 2025, the U.S. FDA’s medical-device user fee program set standard 510(k) fees at $24,335, and higher-risk PMA work can be far costlier, so pipeline growth can quickly lift this line item.

• FDA filings add direct cash costs
• Legal work protects patents and data
• More programs mean higher spend

TriSalus Life Sciences, Inc. uses sales, marketing, and administrative spending to fund its commercial launch, physician education, and core corporate work. The Westminster, Colorado headquarters also adds staff and overhead, and these SG&A costs support market access and day-to-day execution.

• Commercial launch spend
• Physician education support
• Westminster HQ personnel
• Market access execution

Procedure-driven utilization revenue rises when TriSalus Life Sciences, Inc. products are used again and again at treatment centers; every new physician adopter can lift procedure count, turnover, and market reach. In 2025, that repeat-use model mattered because oncology care remained highly visit-based, so adoption depth can matter more than one-off sales.

• More procedures can mean more product turns
• Physician adoption drives repeat use
• Treatment-center volume lifts market penetration

TriSalus Life Sciences, Inc. can monetize its Pressure-Enabled Drug Delivery platform and SD-101 through upfront fees, milestones, and royalties, a common biotech model for platform assets. This non-dilutive income can help fund R&D while direct product sales scale.

• Upfront cash lowers funding pressure.
• Milestones track clinical and regulatory progress.
• Royalties add long-tail upside.

For TriSalus Life Sciences, Inc., partnering income can sit beside product revenue, making cash flows less dependent on one launch.